With Ideaya deal, GSK bulks up synthetic lethality side of oncology business
GSK and Ideaya’s deal is the second in a month to move a pharma deeper into synthetic lethality
A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula.
On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Ideaya Biosciences Inc. (NASDAQ:IDYA) announced a partnership covering three preclinical programs targeting the biosynthetic enzyme MAT2A, the DNA polymerase POLQ, and the DNA helicase WRN.
Ideaya has solved the crystal structures
